EMC-AANL-DOX

EMC-AANL-DOX is a legumain-activated prodrug conjugate of Doxorubicin (DOX) (HY-15142A) . EMC-AANL-DOX shows antitumor activity in mouse models of neuroblastoma (NB), breast cancer (4T1), fibrosarcoma (HT1080), and colorectal cancer liver metastases (CT26) . EMC-AANL-DOX can be used for cancer research[1][2].

Product Specifications

CAS Number

[1431625-66-9]

UNSPSC

12352203

Target

Others

Related Pathways

Others

Field of Research

Cancer

Smiles

OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(CO)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC([C@H](CC(C)C)NC([C@H](CC(N)=O)NC([C@H](C)NC([C@H](C)NC(CCCCCN6C(C=CC6=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C53H67N7O19

Molecular Weight

1106.13

References & Citations

[1]Zhang M, et al. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design. Chem Biol Drug Des. 2018 Feb;91 (2) :534-544.|[2]Cheng Liu, et al. Immune-stimulating soluble doxorubicin-conjugated complex. US20200247842. 2022-05-03.